These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27723882)

  • 1. Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase: A Teachable Moment.
    Akturk HK; Nippoldt TB
    JAMA Intern Med; 2016 Dec; 176(12):1743-1744. PubMed ID: 27723882
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
    Iglesias P; Díez JJ
    Am J Med; 2011 Jun; 124(6):e3-4. PubMed ID: 21605718
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
    Auriemma RS; Galdiero M; Vitale P; Granieri L; Lo Calzo F; Salzano C; Ferreri L; Pivonello C; Cariati F; Coppola G; de Angelis C; Colao A; Pivonello R
    Neuroendocrinology; 2015; 101(1):66-81. PubMed ID: 25592453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone: myocardial infarction and stroke.
    Prescrire Int; 2014 Oct; 23(153):240-1. PubMed ID: 25964971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
    Leese G; Jeffreys R; Vora J
    Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma.
    Steinhoff M; Rochlitz H; Nussbaum G; Georgieva J; Zouboulis CC
    J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):124-6. PubMed ID: 17207191
    [No Abstract]   [Full Text] [Related]  

  • 7. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
    Gillam MP; Middler S; Freed DJ; Molitch ME
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.
    Nickel M; Moleda D; Loew T; Rother W; Pedrosa Gil F
    Int J Impot Res; 2007; 19(1):104-7. PubMed ID: 16728967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cabergoline-resistant prolactinoma patient: new challenges.
    Molitch ME
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
    [No Abstract]   [Full Text] [Related]  

  • 11. European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy.
    Mirone V; Debruyne F; Dohle G; Salonia A; Sofikitis N; Verze P; Fode M; Chapple C;
    Eur Urol; 2017 Aug; 72(2):164-167. PubMed ID: 28249799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Practical aspects of use of hormone replacement therapy with testosterone for age-related androgen deficiency in men].
    Korneev IA
    Urologiia; 2012; (5):122-4, 126-7. PubMed ID: 23342630
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolactinoma treatment status in the cabergoline era].
    Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
    No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
    Werner S
    Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
    [No Abstract]   [Full Text] [Related]  

  • 17. Cabergoline for Cushing's disease: A case report.
    Pascual-Corrales E; Tomás Velázquez A; Zubieta JL; Salvador J; Galofré JC
    Endocrinol Nutr; 2015 Dec; 62(10):516-8. PubMed ID: 26307390
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease.
    Hwang K; Miner M
    Asian J Androl; 2015; 17(2):187-91. PubMed ID: 25652628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.